Forte Biosciences (FBRX) Other Working Capital Changes (2018 - 2019)
Forte Biosciences (FBRX) posted quarterly Other Working Capital Changes of $328000.0 for Q1 2020, up 3744.44% year-over-year from $8531.8 in Q2 2019, and up 203.8% quarter-over-quarter from -$316000.0 in Q4 2019.
Powered by 
Analysis
Forte Biosciences (FBRX) Other Working Capital Changes (2018 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has reported Other Working Capital Changes for 3 consecutive years, with $328000.0 the latest figure, recorded in Q1 2020.
- In Q1 2020, Other Working Capital Changes rose 3744.44% year-over-year to $328000.0; the TTM figure through Mar 2020 stood at $301000.0 (down 60.76% YoY), while the FY2019 annual figure was -$36000.0, down 103.85% from the prior year.
- Other Working Capital Changes climbed to $328000.0 in Q1 2020 per FBRX's latest filing, from -$316000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $3.2 million in Q1 2026 and bottomed at -$1.6 million in Q1 2025.
- Historically, Other Working Capital Changes has averaged $455000.0 across 5 years, with a median of $17000.0 in 2024.
- Annual changes were most pronounced in 2019 — Other Working Capital Changes slumped 281.61% — and 2020, when it soared 3744.44%.
- Forte Biosciences' Other Working Capital Changes stood at $174000.0 in 2018, then plunged by 281.61% to -$316000.0 in 2019, then soared by 203.8% to $328000.0 in 2020.
- Business Quant data shows FBRX's Other Working Capital Changes at $328000.0 in Q1 2020, -$316000.0 in Q4 2019, and $298000.0 in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -9,000.00 |
| Dec 31, 2019 | -9,000.00 |
| Sep 30, 2019 | -9,000.00 |
| Sep 30, 2019 | -9,000.00 |
| Jun 30, 2019 | -9,000.00 |
| Jun 30, 2019 | -9,000.00 |
| Mar 31, 2019 | -9,000.00 |
| Mar 31, 2019 | -9,000.00 |
| Dec 31, 2018 | -9,000.00 |
| Dec 31, 2018 | -9,000.00 |
| Sep 30, 2018 | -1.01 Mn |
| Sep 30, 2018 | -1.01 Mn |
| Jun 30, 2018 | 991,000.00 |
| Jun 30, 2018 | 991,000.00 |
| Mar 31, 2018 | -9,000.00 |
| Mar 31, 2018 | -9,000.00 |